Microarray-based molecular signatures have not been widely integrated into neuroblastoma diagnostic classification systems due to the complexities of the assay and requirement for high-quality RNA. New digital technologies that accurately quantify gene expression using RNA isolated from formalin-fixed paraffin embedded (FFPE) tissues are now available. In this study, we describe the first use of a high-throughput digital system 
Introduction
Neuroblastoma, the most frequent extracranial solid tumor of childhood, exhibits a broad range of clinical behavior and varying response to treatment (Maris et al., 2007) . To ensure that therapy is appropriately tailored, efforts to identify variables that accurately predict outcome have been ongoing for more than 35 years. Recently, an International Neuroblastoma Risk Group (INRG) 4 Classification System has been established that utilizes 7 prognostic variables to stratify patients into very low-, low-, intermediate-, or high-risk cohorts (Cohn et al., 2009 ). Although outcome is excellent for non-high-risk patients, almost half of all patients are classified as high-risk, and less than 50% will be cured with current treatment strategies. At the time of diagnosis, it is currently not possible to distinguish the subset of high-risk patients who will achieve long-term survival from those who will develop progressive disease. The prognostic value of gene expression profiles has been recently evaluated using microarray technologies, and numerous low-and high-risk neuroblastoma signatures have been discovered, tested, and validated (Abel et al., 2011; De Preter et al., 2010; Garcia et al., 2012; Schramm et al., 2005; Schulte et al., 2010; Vermeulen et al., 2009; Wei et al., 2004) . Some of these signatures can sub-stratify patients with high-risk neuroblastoma, identifying a subset of highrisk patients with significantly worse survival, or an "ultrahigh-risk" group (Abel et al., 2011; Asgharzadeh et al., 2006; De Preter et al., 2010; Garcia et al., 2012) . However, incorporating molecular signatures into diagnostic classification systems has proven to be difficult because microarray analysis requires frozen tumor tissue to yield high quality RNA, and these samples are rarely available. The microarray-based assays are also expensive and require complex statistical analyses. The nCounterä System overcomes these limitations. This system utilizes simple technology that captures and counts individual mRNA transcripts with high levels of sensitivity, linearity, multiplex capability, and digital readout. Importantly, different sample types, including highly degraded RNA from FFPE material, can be utilized (Fernandez et al., 2012; Kulkarni, 2011; Payton et al., 2009; Stricker et al., 2013) , and recent studies using the nCounterä System have validated expression signatures obtained using microarray technology (Kulkarni, 2011; Malkov et al., 2009; Northcott et al., 2012) .
Here we describe the first use of a high-throughput digital system to assay the expression of a published "ultra-high risk" neuroblastoma molecular classifier . The 42-gene signature was built from a meta-analysis of neuroblastoma studies performed using oligonucleotide microarray platforms. We show that the prognostic value of this microarray-derived gene signature was validated in a cohort of 107 high-risk neuroblastoma patients using nCounterä technology and RNA isolated from FFPE high-risk neuroblastoma tumor samples.
2.
Materials and methods (Maris, 2010) . Medical records were abstracted at each institution and clinical data including age at diagnosis, stage, MYCN status, ploidy, histology, and outcome were collected. The patients were staged according to the International Neuroblastoma Staging System (Brodeur et al., 1993) and tumor histology was defined as favorable or unfavorable using the International Neuroblastoma Pathologic Classification (INPC) System (Shimada et al., 1999) . A hematoxylin and eosin (H&E) stained section and two to four FFPE scrolls of diagnostic tumor tissue were sent to the University of Chicago. The stained tissue sections were reviewed by a pathologist (PP), and the percentage of viable and necrotic tumor, lymphoid infiltrates and other tissue elements including connective tissue and stroma were assessed.
Only cases with >50% viable neuroblastoma tumor cells were selected for expression profiling. This study was approved by the Institutional Review Board at the University of Chicago and at each of the collaborating institutions.
RNA isolation
RNA was isolated using the RNeasy Ò FFPE kit (Qiagen, Valencia, CA) from two 10-mm sections from each sample. RNA concentration was quantified using UV spectroscopy (Nanodrop Technologies, Wilmington, DE) and integrity assessed using a Bioanalyzer 2100 and RNA Nano Chip assay (Agilent Technologies, Wilmington, DE).
Codeset design and expression quantification
Details of the nCounterä technology (NanoString Technologies, Seattle, WA) have been reported previously (Geiss et al., 2008; Kulkarni, 2011) . Briefly, NanoString designed and manufactured customized probes corresponding to the 42 genes in a previously reported prognostic signature (Table 1) . A codeset specific to a 100-base region of the target mRNA was designed using a 3 0 biotinylated capture probe and a 5 0 reporter probe tagged with a specific fluorescent barcode; creating two sequence-specific probes for each target transcript. Probes were hybridized to 100 ng of total RNA for 19 h at 65 C and applied to the nCounterä Preparation Station for automated removal of excess probe and immobilization of probe-transcript complexes on a streptavidin-coated cartridge. Data were collected using the nCounterä Digital Analyzer by counting the individual barcodes.
Data processing and class prediction analysis
Each codeset included probes for the 42-gene signature, spiked-in External RNA Control Consortium positive and 
negative controls, and reference housekeeping genes (Table  1) . Housekeeping genes were selected by analyzing published neuroblastoma microarray datasets (Asgharzadeh et al., 2006; Oberthuer et al., 2010; Wang et al., 2006) , binning genes into low-medium-and highly-expressed, and then selecting 3 genes for each category with minimal variance across samples. Background hybridization was determined using spiked-in negative controls. All signals below mean background plus 2 standard deviations (SD) were considered to be below the limits of detection, and set to mean background. A normalization factor was calculated from the spiked in exogenous positive controls in each sample and applied to the raw counts from the nCounterä output data. Then, a content normalization factor was calculated from the Geomean of the reference genes and applied to the data previously normalized by the positive control. Probesets were produced in two batches, and several samples were run with both sets of probes to generate a per gene batch correction factor that was applied across the entire data set. Each sample was run in duplicate, and for most analyses, the mean of the sample pairs was used.
Statistical analysis
The methods of KaplaneMeier (Kaplan and Meier, 1958) were used to generate event-free survival (EFS) and overall survival (OS) curves for the entire cohort and for subgroups stratified by established risk factors using Prism 5 (GraphPad Software, Inc., La Jolla, CA). The curves were compared using a log-rank test. Five-year EFS and OS rates were expressed as the estimate AE the standard error (SE).
To test the prognostic signature described by De Preter and colleagues, cross-platform data for the 42 genes from the 250 patients in their training set were obtained . Following methods reported by these investigators , a prognostic vector was created by subtracting the mean expression value in patients with EFS of at least 1000 days from the mean expression value from the patients who died of disease for each of the 42 genes. For classification of each of the 107 individuals in our study, the Spearman's correlation coefficient was calculated between the log transformed, normalized nCounterä data, and the vector from the De Preter training data. Patients with a negative correlation coefficient were predicted to have low-molecular risk and a favorable prognosis, whereas patients with a positive correlation had high-molecular risk and an unfavorable prognosis. Survival functions (low versus high-molecular risk) were compared with the log-rank test using the survival package in R. Heatmaps were generated using Heatmap.2, and Principal Components Analysis (PCA) was performed using the pcaMethods packages in R. MYCN targets were identified by taking the union of the following gene sets in MdbSig3.0: MYC_amplified_leukemia, MYC_amplified, MYC_targets_up, and MYC_targets_down. (Shimada et al., 1999) .
Figure 1 e KaplaneMeier curves of OS and EFS of the entire cohort of patients with high-risk neuroblastoma (n [ 107).
3.
Results

Analytic cohort of 107 high-risk neuroblastoma patients
A total of 138 high-risk patients with available paraffinembedded material were identified at the 6 participating institutions. Review of the medical records revealed that 5 cases were misclassified as high-risk. Tumor tissue was not available in 5 cases, as the diagnosis was made using bone marrow samples. In 10 cases, tumor cellularity was <50%. RNA was isolated from 118 tumors. For 11 samples the data quality was poor as determined by correction factors >10, >20% of the genes were expressed below the threshold, and/or overall means were 3 or more SD above or below the mean for all samples following correction and normalization. Although many of samples with poor data quality were needle-core biopsies, we were able to generate high quality expression data from 8 core needle biopsy samples. Thus, the size of the core needle biopsies and the amount of viable tumor in these samples are important determinants of data quality. We were able to generate high quality expression data for 107/118 cases (90.7%), using FFPE material, and these patients comprised the analytic cohort for this study.
Patients ranged in age from 3 days to 184 months, with a mean of 38 months. Eighty-three (77.6%) patients were older than 18 months (Table 2) . Eighty-seven (81.3%) patients had stage 4 disease, and MYCN amplification was detected in tumors from 61 patients (57%). All patients were either enrolled on or treated according to a cooperative group clinical trial or institutional high-risk neuroblastoma protocols (Furman et . Five-year EFS and OS rates AESE for the entire cohort were 43% AE 5.2% and 52% AE 5.3%, respectively (Figure 1 ). Age at diagnosis, stage of disease, tumor histology, MYCN status, and ploidy were not statistically significantly predictive of outcome (Table 2) .
Integrity of RNA from FFPE blocks is sufficient for nCounterä analysis
The integrity of the RNA determined by the Bioanalyzer varied from a RIN of 1.2e2.8, confirming that the RNA purified from FFPE blocks is highly degraded. Although RNA with RINs of 7.5 or greater is generally recommended for microarray experiments, chains that are at least 100 base pairs long were suitable for hybridization with the capture and reporter probes using the nCounterä system. 
3.3.
Gene expression cluster analysis shows correlation with MYCN status
The nCounterä measurements were highly reproducible. Pearson correlation coefficients were calculated for each of the duplicate samples and ranged between 0.925 and 0.997 (mean of 0.98) (Figure 2A ). Furthermore, a linear regression was performed on all pairs, and the R-squared values ranged between 0.855 and 0.995 with a mean of 0.96 ( Figure 2B ). Unsupervised clustering of the 42 genes tested within our cohort showed that samples clustered into three groups, largely defined by expression of MYCN ( Figure 3A) . The MYCN high expressing group consisted of cases with MYCN amplified tumors, but there were some non-amplified cases in this group as well. Interestingly, although these tumors clustered with the MYCN amplified tumors, their MYCN expression levels were lower than that observed in the amplified tumors, indicating that they are similar to amplified tumors on the basis of other genes in the signature. The other two groups had lower levels of expression of MYCN. Of note, while these were mostly non-amplified tumors, there were some amplified tumors in these clusters that, while they expressed MYCN, they did so at levels closer to non-amplified tumors. The heat map demonstrates that duplicate samples were highly correlated; for every sample, the most closely related sample was the replicate ( Figure 3A) . Thus, the mean expression level for each replicate was calculated and used in all subsequent experiments.
A heat map of the mean values showed similar segregation of tumors by MYCN expression ( Figure 2C) . PCA of the expression levels for 42 genes also demonstrated a strong separation between samples with versus without MYCN amplification ( Figure 3B ). MYCN gene expression clearly segregated into high and low expression groups, and the level of expression correlated strongly with MYCN amplification status ( Figure 2D ). Eighty-nine percent (54/61) of MYCN amplified cases also had high expression of MYCN. Likewise, of the samples with high MYCN expression, only 4 did not have MYCN amplification. In addition, high MYCN gene expression correlated with expression of known MYC target genes (i.e. ODC1, PAICS, NME1) (BenYosef et al., 1998) ( Figure 3C ). De Preter and colleagues noted that 12 of the 42 genes in the signature are known targets of MYCN . We found that expression of all 12 of these genes strongly correlated with MYCN status in our cohort. To specifically determine the correlation between each of the genes in the signature and MYCN status, differentially expressed genes in the MYCN amplified versus non-amplified cases were quantified via linear model, followed by correction for multiple hypothesis testing using Storey's q-value method (Storey, 2002) . Twenty-eight of the 42 genes in the signature were statistically significantly differentially expressed in the MYCN amplified cases compared to the non-amplified tumors, including the known MYC targets CAMTA1, NME1, and NTRK1. However, 14 additional genes, including PLAGL1, AKR1C1, ARH-GEF7, CADM1, CAMTA2, EPB41L3, and FYN, showed little correlation with MYCN status (Figure 3C and D) . 
3.4.
The multi-gene expression signature analyzed with the nCounterä system sub-stratifies high-risk neuroblastoma
The nCounterä 42-gene panel sub-stratified the cohort of 107 high-risk patients into two groups with statistically significantly different outcome, replicating the results of De Preter et al. (2010) Patients with low-versus high-molecular risk tumors had OS rates of 57.3% AE 7.8% versus 36.7% AE 7.7%, respectively ( p ¼ 0.0027) ( Figure 4A ), and EFS of 48.8% AE 7.7% versus 29.3% AE 7.4% ( p ¼ 0.028) ( Figure 4B ). The 42-gene signature was also prognostic within the subset of 38 high-risk patients with non-MYCN amplified tumors, with OS of 55.8% AE 10% versus 28.6% AE 17% ( p ¼ 0.0056) for patients with low vs highrisk molecular tumors ( Figure 4C ), and EFS of 54.6% AE 9.8% versus 14.3% AE 13.2%, respectively ( p ¼ 0.011) ( Figure 4D ).
Discussion
In this study, we validated the prognostic significance of a published neuroblastoma microarray signature that was previously shown to sub-stratify high-risk patients into cohorts with significantly different survival using high throughput digital technology and RNA isolated from 107 FFPE high-risk tumors. The cohort of high-risk patients with worse outcome is considered at "ultra-high risk" for relapse. The nCounterä system requires very small amounts of RNA, and reliable results can be obtained even if the RNA is highly degraded. This technology has numerous advantages over microarray methodology including the ability to analyze gene expression using FFPE tumor tissue as starting material. The workflow does not involve enzymatic and amplification steps, thus reducing the risk of additional technical errors and the introduction of bias in the results. Furthermore, this digital technology is less time consuming, requires only a simple data analysis and normalization strategy, and is less expensive and more reproducible (Malkov et al., 2009 ). The multi-gene signature analyzed in our study originated from an analysis of 933 neuroblastoma patients from eight independent studies . This molecular classifier was established based on reanalysis of published studies with updated clinical information, re-annotation of the probe sequences, common risk definitions for training cases, and a single method for gene selection (prediction analysis of microarray) and classification (correlation analysis). Using new digital technology, we replicated the findings of De Preter et al. (2010) and show that the 42-gene classifier sub-stratified high-risk neuroblastoma patients into subsets with significantly different outcome. The signature was also prognostic within the subset of patients with tumors that lacked MYCN amplification. In contrast, none of the other established prognostic markers was associated with outcome.
Interestingly, although 28 of the 42 genes were statistically differentially expressed between MYCN amplified and non-amplified cases, the signature determined prognosis in the whole cohort as well as the non-MYCN amplified group.
In fact, this signature was prognostic while MYCN status was not in our cohort. It is important to note that not all genes are associated with MYCN status, and thus this signature doesn't just represent MYCN copy number status. Indeed, it can be seen from the heatmap that while amplified and non-amplified tumors mostly cluster separately, there are non-amplified tumors clustering with the amplified tumors and vice versa. Future studies will explore the hypothesis that the expression signature, rather than MYCN amplification status, is a more accurate measurement of MYCN pathway activation, and thus, a better discriminator for outcome.
Despite the prognostic value of this 42-gene ultra-high risk signature , it has not been prospectively studied or integrated into a neuroblastoma classification system, due in part to the requirement for frozen tumor and high quality RNA isolation for the microarray assay. Although frozen tumors are not readily available, the vast majority of patients with high-risk neuroblastoma have FFPE tumor samples. RNA extracted from FFPE material is typically highly degraded, and therefore of limited use in other molecular studies. The nCounterä technology overcomes this obstacle by using relatively short 50mer probes that will hybridize efficiently with RNA chains as short as 100 base pairs (each target gene hybridizes with one capture and one reporter probe). As we show, the highly degraded RNA from FFPE tumor samples is sufficient to obtain strong gene expression signals that are highly reproducible.
The ability to identify patients who will not adequately respond to standard high-risk treatment strategies in the diagnostic setting is critical for informed treatment decisions. Prospective clinical trials will be needed to identify the most powerful prognostic classifiers for high-risk neuroblastoma patients. Using the nCounterä System, data can be generated in w24 h and analytic results can be obtained within a few weeks. Thus, this technology is well suited for evaluating expression signatures in newly diagnosed patients. With more precise prognostication, "ultra-high-risk" patients could be spared unnecessary acute and long-term toxicities associated with current, intensive multi-modality therapy approaches. Transitioning patients who are not likely to survive with standard therapy to alternative treatments and/ or early phase clinical studies may provide the clinical benefit of more targeted, less toxic treatments and improved quality of life.
